(2R)-daptomycin
Sign in to saveDaptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Key facts
- Drug.ChEBI
- 600103
- Drug.ChEMBL
- 508162
- Drug.O
- 26
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 457630808
- Drug.image
- Daptomycin Ball et al.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.tradename
- Cubicin, Cubicin RF, Dapzura RT
- Drug.DailyMedID
- Daptomycin
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J01
- Drug.ATC_suffix
- XX09
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Article
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Microbiology
- Daptomycin resistance
- Efficacy
- Biosynthesis
- History
- References
- Further reading
- External links
Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Daptomycin was removed from the World Health Organization's List of Essential Medicines in 2019. The World Health Organization classifies daptomycin as critically important for human medicine.
Gallery (6)
Connections
Categories
AntibioticsCyclic peptidesDepsipeptidesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by AstraZenecaDrugs developed by Eli Lilly and CompanyDrugs developed by Merck & Co.Drugs with non-standard legal statusECHA InfoCard ID from WikidataLipopeptidesPeripheral membrane proteins